Context Therapeutics (NASDAQ:CNTX) Upgraded by Citizens Jmp to “Strong-Buy” Rating

Citizens Jmp upgraded shares of Context Therapeutics (NASDAQ:CNTX) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Several other equities analysts also recently issued reports on the company. D. Boral Capital began coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities initiated coverage on Context Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $4.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $6.33.

Context Therapeutics Price Performance

NASDAQ:CNTX opened at $1.21 on Wednesday. The firm has a market capitalization of $90.75 million, a P/E ratio of -1.33 and a beta of 2.10. The business has a 50 day simple moving average of $1.52 and a 200 day simple moving average of $1.94. Context Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently modified their holdings of CNTX. Y Intercept Hong Kong Ltd purchased a new stake in shares of Context Therapeutics in the 3rd quarter valued at approximately $89,000. Renaissance Technologies LLC lifted its position in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after buying an additional 25,300 shares in the last quarter. State Street Corp grew its holdings in shares of Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after buying an additional 1,290,323 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in Context Therapeutics in the third quarter worth approximately $3,689,000. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.